Photoshop CS5 tutorial showing how to make a sheet of crumpled paper from scratch using simple techniques. Dietitians say you shouldn't take these vitamins in the morning Trump’s new warning and ...

Maze Therapeutics (MAZE) plunged ~37% on Wednesday despite reporting encouraging initial data from a Phase 2 trial for its lead asset, MZE829, targeted at broad APOL1-mediated kidney disease, a ...

Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” The once-daily oral small molecule APOL1 inhibitor, ...

A Canadian who has worked in the gaming industry for over two decades, Beck grew up on games such as Final Fantasy and Super Mario Bros. He specalizes in roleplaying games, but covers titles in almost ...

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host ...

Chief Medical Officer Harold Bernstein exercised 15,000 shares, which were sold immediately for a total transaction value of approximately $690,300 on Feb. 2, 2026. Maze Therapeutics recently hit its ...

Maze Therapeutics (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, visits the Nasdaq MarketSite ...

Maze Therapeutics leverages its Compass platform to translate human genetic insights into de-risked, high-probability drug candidates. MZE829 targets APOL1-mediated kidney disease with a dual ...

NASHVILLE, Tenn. (WKRN) — A Nashville man convicted more than two decades ago in the death of his infant son is asking for his case to be heard one more time. Attorneys for Russell Maze have filed a ...

Dr. Bruce Levy's finding that Alex Maze died of shaken baby syndrome was critical in the murder conviction of his father, Russell Maze. Decades later, Levy says he believes Maze is innocent. In the ...

Monday - Friday, 2:00 - 3:00 PM ET In this article Maze Therapeutics has had a great run since its initial public offering in January — and CEO Jason Coloma is hoping that momentum continues as the ...

Add Popular Science (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.